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Abstract 
Increasing life expectancy has led to an aging population, which has consequently increased the prevalence of 
dementia. Alzheimer’s disease (AD), the most common form of dementia worldwide, is estimated to make up 50–80% 
of all cases. AD cases are expected to reach 131 million by 2050, and this increasing prevalence will critically burden 
economies and health systems in the next decades. There is currently no treatment that can stop or reverse disease 
progression. In addition, the late diagnosis of AD constitutes a major obstacle to effective disease management. 
Therefore, improved diagnostic tools and new treatments for AD are urgently needed. In this review, we investigate 
and describe both well‑established and recently discovered AD biomarkers that could potentially be used to detect 
AD at early stages and allow the monitoring of disease progression. Proteins such as NfL, MMPs, p‑tau217, YKL‑40, 
SNAP‑25, VCAM‑1, and Ng / BACE are some of the most promising biomarkers because of their successful use as 
diagnostic tools. In addition, we explore the most recent molecular strategies for an AD therapeutic approach and 
nanomedicine‑based technologies, used to both target drugs to the brain and serve as devices for tracking disease 
progression diagnostic biomarkers. State‑of‑the‑art nanoparticles, such as polymeric, lipid, and metal‑based, are being 
widely investigated for their potential to improve the effectiveness of both conventional drugs and novel compounds 
for treating AD. The most recent studies on these nanodevices are deeply explained and discussed in this review.
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Highlights
• Alzheimer’s disease is the most common form of 
dementia worldwide, estimated to be responsible for 
50–80% of all cases.
• No currently available treatment can stop the disease 
progression, and it is expected that AD cases will 
reach 131 million by 2050.
• The late diagnosis of AD will have a serious impact 
on health and socio-economic systems worldwide.
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• Novel biomarkers, such as NfL, SNAP-25, Clusterin, 
MMPs, and YKL-40, among others, are being studied 
alongside commonly used biomarkers as potential 
new diagnostic tools.
• Nanomedicine has aroused much interest in the last 
decade and has shown promising results for improv-
ing drug targeting and delivery to the brain.
• Polymeric-, lipid-, and metal-based nanoparticles are 
the most commonly investigated nanodevices in the 
field of dementia.
• State-of-the-art nanoparticles are emerging as prom-
ising tools to improve the diagnosis and treatment of 
AD.
Introduction
In the past few decades, the number of people living 
with dementia has increased exponentially all around 
the world, mainly due to aging populations and improve-
ments in quality of life. The latest Global Burden Disease 
Study estimated that the number of cases of demen-
tia more than doubled from 1990 to 2016 and indicated 
population growth and aging as the main drivers of this 
increase (Fig. 1) [1].
Alzheimer’s disease (AD) is the most common form 
of dementia worldwide, estimated to constitute up to 
50–80% of cases [1]. Undoubtedly, AD will critically 
burden economies and health systems since cases are 
expected to reach 131 million by 2050 [2]. AD is com-
monly diagnosed symptomatically through the occur-
rence of significant memory loss, global cognitive 
decline, and the impairment of daily life activities. Later 
in the course of the disease, the breakdown of physi-
cal functions, such as walking, swallowing, and general 
movement, ultimately leads to death [3]. Dementia was 
the fifth-leading cause of death in 2016 [1].
AD can be classified depending on the onset of the 
first symptoms. Approximately 1–6% of all cases are cat-
egorized as early-onset AD (EOAD), which manifests 
before the age of 65. By contrast, late-onset AD (LOAD) 
is characterized by the occurrence of symptoms at an 
age greater than 65  years and accounts for around 90% 
of cases [4]. EOAD differs from LOAD in many aspects. 
Prominently, EOAD has a more aggressive course of 
disease progression, greater delay to diagnosis, lower 
cognitive reserves, lower incidence of diabetes, obesity, 
and circulatory disorders, relatively greater deficits in 
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Fig. 1 Global deaths (D) and prevalence (P) for Alzheimer’s disease and other dementias in 2016. Data are n (95% UI). UI = uncertainty interval. Data 
extracted from the Global Burden of Disease Study of Alzheimer’s disease and other dementias 2016 [1]
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functions, lower frequency of the APOE ε4 allele, greater 
white matter changes, and a higher burden of neuritic 
plaques and neurofibrillary tangles [5].
In general, AD is defined as a multifactorial disease in 
which genetic, environmental, behavioral, and develop-
mental components critically influence its pathogenesis, 
with age being the most important risk factor. Although 
most cases of AD are sporadic, rare cases (< 1%) have 
a genetic component (“Familial AD”, FAD) with a few 
hundred families identified worldwide. These cases usu-
ally have an early onset at young ages (40–50). The three 
known genes that cause FAD, with an autosomal domi-
nant inheritance, are the amyloid precursor protein 
(APP), presenilin-1 (PS1), and presenilin-2 (PS2) genes, 
all of which are involved in the processing or production 
of Aβ [6]. Our understanding of the pathophysiology of 
AD is constantly changing [4]. The overproduction and 
accumulation of amyloid-β (Aβ) peptide and hyperphos-
phorylated tau (p-tau) protein are the two most com-
mon hypotheses for AD pathogenesis, but recent findings 
have demonstrated that chronic oxidative stress, hor-
mone imbalance, mitochondrial dysfunction, inflamma-
tion, calcium mishandling, mitotic dysfunction, genetic 
components or blood–brain barrier (BBB) dysfunction 
also likely play key roles in the disease process [7, 8]. 
Similarly, emerging studies have also reported that oli-
godendrocytes act as antigen-presenting cells and pro-
duce immune molecules. Likewise, the activation of 
both astroglia and oligodendrocytes, mainly due to BBB 
dysfunction and general toxic species produced in AD, 
occurs widely in AD [9]. In neuroinflammation processes, 
oligodendrocytes express many factors known to activate 
astrocytes. In response to these factors, astrocytes and 
oligodendrocytes secrete immune factors, underscoring 
the possible immune function of these cells. IL-1β, IL17 
tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), 
and fibroblast growth factor-2 (FGF-2) are some of these 
secreted cytokines that induce pro-inflammatory effects 
[9]. Regardless of all these changes, neuronal death is the 
ultimate invariable outcome, which then drives the typi-
cal neurodegeneration of AD.
Currently there are only four FDA approved treatments 
for AD, and these are linked mainly to the two molecular 
pathways involving the accumulation of Aβ peptide and 
neurofibrillary tangles (NFT) of p-tau protein [10]. How-
ever, none of these drugs stops disease progression or 
cures AD, highlighting the need for additional treatment 
approaches. The discovery of novel biomarkers is hoped 
to deliver earlier AD diagnosis and could also support the 
identification of additional molecular targets, potentially 
leading to new treatments.
Identifying the pathophysiological processes involved 
in AD and the best biomarkers to detect them is critical 
for the development of novel cures. In addition, effi-
ciently and specifically delivering the diagnostic and 
therapeutic molecules to the sites of interest in these pro-
cesses is critical. Nanoparticles (NPs) have enabled great 
strides towards the delivery, treatment and diagnostics of 
diseases, mainly due to their various chemical character-
istics and their propensity for chemical modification to 
modulate and refine required properties [11, 12]. NPs’ 
core constituents comprise a wide variety of materials, 
such as lipids, polymers, and metals, that can encapsu-
late molecules with different chemical natures. In addi-
tion, these carriers promote the protection and delivery 
of bioactive molecules, which can reduce their potential 
toxicity and, in turn, enhance their solubility, stability, 
biodistribution, and pharmacokinetics. Molecules encap-
sulated in NPs range from small molecules, peptides, and 
proteins to genetic material [13]. Crucially for chronic 
CNS diseases, NPs have the demonstrated capacity to 
deliver molecules to hard-to-reach tissues, such as the 
CNS where the crossing of the BBB and the release of 
drugs with controlled kinetics for long-term treatments 
are required [11, 14].
In this review, we investigate and describe well-estab-
lished AD biomarkers and highlight recently discovered 
ones that could be potential diagnosis tools. In addition, 
we explore the most recent nanomedicine-based tech-
nologies used to target drugs across the BBB and increase 
CNS delivery of these active molecules.
Novel biomarkers in the diagnosis of Alzheimer’s 
Disease
AD was first described in 1906 [15]. For a long time after 
that, firm diagnosis was made when signs of memory loss 
and cognitive decline were already significantly advanced. 
Nowadays, many observations indicate that the patho-
physiological alterations of AD in the brain begin dec-
ades before the onset of clinical symptoms of dementia. 
Historically, AD patients were classified into three clini-
cal categories: cognitively unimpaired (CU), mild cogni-
tive impairment (MCI), and dementia patients [16]. AD 
is now recognized as a continuum of neurological decline 
that can be identified and staged through a combination 
of neuropathological findings and in  vivo biomarkers 
[17, 18]. This has led to a paradigm shift in the diagnosis 
of AD, opening new windows of opportunities for early 
treatment in the preclinical stages. In that context, the 
National Institute on Aging and the Alzheimer’s Asso-
ciation have recently updated diagnostic criteria, with a 
clear shift from a clinical to a biological definition of AD 
[19].
Biomarkers now have key importance in the robust 
diagnosis of AD. Biomarkers are quantifiable mol-
ecules or processes that can be related to the biological 
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alterations and/or pharmacologic responses to a thera-
peutic intervention for a specific disease [18, 20]. An 
ideal biomarker should be specific, sensitive, predictive, 
accurate, robust, inexpensive, and ideally non-invasive 
and measurable in common biological fluids such as 
serum, saliva and/or urine [21, 22]. For AD, cerebro-
spinal fluid (CSF) is considered the optimal biological 
source for biomarker assessment, since its direct contact 
with the interstitial fluid where the brain is immersed 
reflects the pathophysiological changes of AD progres-
sion in real time [18, 23]. For AD biomarkers, specificity 
and sensitivity of more than 80% are needed to be con-
sidered a reliable biomarker [18]. Notably, not all patients 
with cognitive impairment develop Aβ plaques or tau 
neurofibrillary tangles (NFTs), and vice versa. Further-
more, biomarkers have different uses and interpretations 
depending on the degree of the cognitive deterioration 
observed. Thus, the use of biomarkers has allowed the 
identification of prodromal AD in MCI subjects and the 
confirmation of AD in individuals with dementia [18].
Several biomarkers are currently being used in a com-
plementary way with conventional neuropsychological 
tests and routine neurological exams in the diagnosis of 
AD. The parameters and diagnostic implications of these 
conventional biomarkers have recently been reviewed 
and updated. Furthermore, new molecules, related to 
different pathophysiological pathways involved in the 
development of AD, are being identified as potential new 
biomarkers for the early diagnosis of this disorder (Fig. 2) 
[24–27].
Conventional AD biomarkers in CSF/plasma
Aβ‑related biomarkers
In AD pathogenesis, the production of Aβ peptides is 
increased, while their clearance is reduced. Aβ1-40 and 
Aβ1-42 fragments predominantly form, promoting the 
aggregation of these peptides and thus leading to the for-
mation of senile plaques [28]. Aβ42 is one of the most 
toxic isoforms of the Aβ peptide and is also one of the 
most widely accepted biomarkers of AD diagnosis [29, 
30]. Aβ42 quantification in CSF allows the identification 
of AD in its preclinical stage, and possesses high diagnos-
tic value with clear specificity for AD over other neurode-
generative diseases. However, absolute Aβ42 levels vary 
due to a variety of factors, particularly interindividual 
differences [29]. To account for these, the ratio between 
Aβ42/Aβ40 is also commonly used. Aβ40 concentration 
is 10-times higher than Aβ42 in CSF and its level does 
not usually vary in AD [31]. Similarly, the Aβ42/Aβ38 
ratio is emerging as a potential predictive tool with com-
parable power to the Aβ42/Aβ40 ratio [32–34].
Likewise, as with other disease biomarkers, current 
efforts are also focused on improving Aβ42 detection in 
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Fig. 2 Conventional and novel biomarkers related to molecular alterations and physiopathological changes of AD
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function is an invasive procedure that is only permit-
ted for certain patients. It is often not feasible, e.g., for 
patients with low back injuries, increased intracranial 
pressure due to a space-occupying lesion, coagulopathy, 
or infected skin over the puncture site [35, 36]. Immuno-
precipitation coupled with mass spectrometry, ELISA, 
and protein misfolding cyclic amplification assays are 
possible techniques for detecting blood Aβ42 [29, 37]. 
Recently, a blood analytical test for the detection of 
plasma Aβ by mass-spectrometry gained approval by reg-
ulators at the Centers for Medicare & Medicaid Services 
under the Clinical Laboratory Improvement Amend-
ments protocol [38]. Researchers predict that the next 
tests to be approved are plasma p-tau181 and p-tau217, 
as these tests will be more robust since they possess a 
larger dynamic range. Indeed, phosphorylated fragments 
of tau increase by as much as tenfold in the blood as AD 
progresses, whereas the Aβ42/40 ratio falls by about 15 
percent at most [38].
BACE1, the key enzyme that initiates the formation of 
Aβ peptide [39], has increasingly been studied as a poten-
tial AD biomarker. BACE1 can be measured in CSF, but 
there is controversy regarding its predictive value. Some 
studies have shown increased levels and protein activity 
of BACE1 in AD patients and that this is a good predic-
tor of the progression of MCI patients [40, 41]. However, 
more recent studies have reported no changes in CSF 
BACE1 levels among controls, MCI and AD patients 
[42–44].
Tau‑related biomarkers
It is widely accepted that hyperphosphorylated tau 
(p-tau), accumulating as intracellular NFTs, is the other 
main pathological hallmark of AD, together with Aβ 
plaques [29, 45]. However, in many neurodegenerative 
diseases, collectively known as "tauopathies", p-tau NFTs 
are found that differ in their phosphorylated residues 
[29, 46]. The diagnostic value of total tau (t-tau) levels for 
differentiating AD from normal aging is well described. 
T-tau has been considered a relevant biomarker of neu-
ronal injury and thus is not a specific marker of AD; it 
is also found to be elevated in other neurological condi-
tions such as Creutzfeldt-Jakob’s disease, frontotemporal 
dementia with parkinsonism, and Pick’s disease, among 
others [47]. P-tau (specifically tau phosphorylated on 
threonine 181, p-tau181) has been described as a more 
specific biomarker for AD since p-tau is present at nor-
mal levels in most other neurodegenerative disorders, 
but not in AD [29]. In clinical practice, the correlation 
between both t-tau and p-tau in CSF is important for dif-
ferentiating among several dementia types [48].
Levels of tau deposition display a stronger correlation 
to cognitive decline than does Aβ in AD patients [49]. 
However, longitudinal studies have revealed that CSF tau 
levels vary depending on the different stages of the dis-
ease [49, 50]. Several recent studies have tried to eluci-
date the prognostic value of tau in early-onset AD and 
as a biomarker to monitor drug responses, but further 
investigation is required [29].
As with Aβ, progress is also being made regarding the 
predictive value of tau in blood samples thanks to ultra-
sensitive immunoassays techniques. Some studies have 
already identified higher plasma and/or serum p-tau181 
levels in AD patients versus controls using innovative 
techniques such as Simoa®, immunomagnetic reduc-
tion, and label-free real-time surface plasmon resonance 
[51–53]. Interestingly, recent findings have shown the 
predictive value of plasma p-tau217 for discriminating 
AD from other neurodegenerative diseases, specifically 
as an accurate predictor of β-amyloidosis at asympto-
matic and symptomatic stages [54–57]. In these stud-
ies, p-tau-217 and p-tau-181 were highly specific for 
amyloid plaque pathology, as p-tau-217 measurement 
was still more specific to amyloid status than p-tau-181 
[54–57]. Collectively, these findings raise the possibility 
for a novel, highly sensitive, and specific biomarker based 
on circulating tau, with improved diagnostic accuracy. 
Further studies are needed to validate these findings in 
unselected and diverse populations and determine its 
potential role in clinical practice [54–57].
Novel AD biomarkers in CSF/plasma
Neuronal damage‑related biomarkers
Other molecules and cellular structures have been sug-
gested as potential biomarkers of neuronal damage. 
Among these, neurofilaments, specifically neurofilament 
light chain (NfL), have emerged as promising biomarkers. 
After axonal and/or neuronal damage, NfL leaks into CSF 
and increases to detectable levels [58].
Although NfL is not specific to AD, it has been shown 
to be intimately linked to neurodegenerative diseases, 
and its predictive value increases in combination with 
other biomarkers [59]. However, one of the benefits of 
NfL compared to other biomarkers is the high correla-
tion of its levels in CSF and blood [60]. Moreover, simi-
larly to Aβ, increased levels of NfL can be detected in 
the early stages of autosomal dominant AD, even before 
the onset of first symptoms [61]. In addition, a recent 
18-month trial with mild AD patients showed that NfL, 
as a Tau-independent marker of axonal degeneration, had 
a stronger association with clinical scales than did t-tau 
[62]. Thus, the ability of NfL to detect changes before 
clinical manifestations occur reveals its promise as a 
diagnostic biomarker.
Visinin-like protein 1 (VILIP-1), a calcium sensor pro-
tein highly expressed in neurons, is another protein that 
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could act as a biomarker of neuronal-injury in AD [18, 
29]. This is supported by the strong correlation between 
increased levels of both VILIP-1 and tau in the CSF of 
AD patients [63, 64]. Importantly, some studies have 
reported the predictive value of VILIP-1 for atrophy 
rates and cognitive decline, indicating that this protein 
could help identify MCI patients that will progress to AD 
[64]. In blood samples however, the predictive value of 
VILIP-1 remains uncertain [27, 29].
Neuroinflammation‑related biomarkers
Inflammatory processes play important roles in the 
pathogenesis of AD. The activation of glial cells, the resi-
dent immune cells of the CNS, is well described for dif-
ferent neurodegenerative diseases, especially AD [65, 66]. 
Historically, it was accepted that neuroinflammation, ini-
tiated primarily as a reaction to Aβ and p-tau neurotoxic-
ity, triggered the production of neurotoxic molecules (e.g. 
ROS, glutamate or inflammatory cytokines). This pat-
tern is reproduced in a continuous molecular feedback 
loop, which has been described to be more pronounced 
in late stages of AD [67]. However, recent evidence also 
reveals the neuroprotective role of microglia and astro-
glia in earlier stages of AD development [67, 68]. When 
the deposition of Aβ plaques appears, glial cells create an 
immune barrier that surrounds and isolates these senile 
plaques. This process protects the axons adjacent to Aβ 
plaques from Aβ neurotoxicity [50, 60]. Recent genetic 
studies have found correlations between the deficiency 
of microglia encapsulation toward Aβ deposits and an 
increased risk of late-onset AD [53, 58]. In addition, an 
inverse correlation between neuroinflammation in the 
brain cortex and plasmatic NfL levels has been reported 
[69, 70]. In normal aging, serum levels of NfL show a 
nonlinear increase from 60 years old in both males and 
females [71]. However, low plasma NfL levels are associ-
ated with raised cortical microglial activation, suggesting 
that inflammation acts to protect prodromal AD [70].
Consequently, neuroinflammation biomarkers may be 
of great interest for the early diagnosis of preclinical AD. 
YKL-40, also known as human cartilage glycoprotein 39 
and predominantly related to astroglial proteins, is one 
of the most studied neuroinflammation-related biomark-
ers [72]. YKL-40 is not only upregulated in AD, but in 
other diseases in which inflammation plays an important 
role [72]. Longitudinal studies and recent meta-analyses 
have reported that CSF YKL-40 levels are higher in AD 
patients compared with controls, increase throughout 
the disease progression and are positively correlated 
with neuronal-injury biomarkers, mainly in the preclini-
cal stages of AD [30, 64]. However, YKL-40 has not yet 
shown consistent results in blood samples.
Progranulin, a glycoprotein mainly secreted by acti-
vated microglia, is involved in the modulation of neuroin-
flammation [73]. This protein has aroused much interest 
since its loss-of-function has been closely correlated with 
some types of frontotemporal lobar degeneration [29, 
74]. However, although a cross-sectional study reported 
increased CSF progranulin levels in autosomal-dominant 
AD and late-onset AD, progranulin from CSF or blood is 
currently not validated as diagnostic markers [75, 76].
Another neuroinflammation-related biomarker 
that has attracted attention is the triggering receptor 
expressed on myeloid cells 2 (TREM2), which has an 
arguably controversial role in AD development. This 
transmembrane protein belongs to the immunoglobulin 
family and is expressed in microglial cells [77]. TREM2 
is involved in many biological processes, such as migra-
tion, proliferation, cytokine release, APOE binding, or 
sealing of Aβ plaques [29, 68]. Moreover, a rare missense 
mutation, predicted to lead to an R47H substitution in 
TREM2, has been linked to a significant risk of AD in 
Iceland [78]. It was also reported that the soluble ecto-
domain of TREM2 (sTREM2) is released into the extra-
cellular space and may serve as a CSF biomarker [29]. 
However, to the best of our knowledge, the biological 
role of sTREM2 is unclear, particularly in neuroinflam-
mation. Some studies have shown that hyperstimulation 
of the TREM2 pathway correlates to the attenuation of 
microglial activation [79–81]. However, further studies 
are needed to provide firm mechanistic evidence.
Taken together, most of these inflammation-related 
biomarkers are not specific to AD and have thus been 
proposed as “neuroinflammation-tracking assistants” 
that can provide a more solid diagnosis together with 
specific AD biomarkers. Additionally, they could be used 
to identify AD patients who would benefit from novel 
microglia-targeted treatments.
Synaptic dysfunction‑related biomarkers
Synaptic degeneration is another hallmark of early AD 
pathology and appears to closely correlate with cognitive 
decline [82]. This event is associated, in turn, with the 
neurotoxic effects of Aβ and tau species and glutamater-
gic excitotoxicity, which lead to alterations in axonal 
transport that later promote dendritic alterations and 
eventually neuronal loss [83]. Many molecules involved 
in synaptic degeneration have been identified as poten-
tial biomarkers and have been divided into pre- and post-
synaptic biomarkers.
Growth-associated protein 43 (GAP-43) belongs to 
the group of potential presynaptic biomarkers [27, 29]. 
This protein is involved in synaptogenesis and neuronal 
development and is mainly expressed in the cortex, hip-
pocampus, olfactory bulb, and cerebellum. In fact, three 
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decades ago, the correlation between an increased den-
sity of neurons containing NFTs and decreased levels of 
GAP-43 in the brain and cerebellar cortex of AD patients 
had already been reported [84]. More recently, the signif-
icant elevation of CSF GAP-43 in AD patients has been 
reported [85]. Interestingly, this increase also correlates 
with the amount of Aβ and p-tau found in the cortex, 
amygdala and hippocampal structures [85]. These find-
ings indicate that GAP-43 is a promising biomarker for 
AD in CSF. However, its usefulness in blood samples has 
not yet been well described.
Synaptosomal-associated-protein-25 (SNAP-25) is a 
newly discovered potential biomarker related to pre-syn-
aptic damage. Recent studies reported that CSF SNAP-25 
increases in MCI and AD, which is associated with the 
rate of hippocampal atrophy and cognitive decline [86]. 
Moreover, CSF SNAP-25 levels are also substantially 
higher in MCI patients who are APOE ε4 carriers, com-
pared to non-carriers. These findings suggest the poten-
tial relevance of SNAP-25 to predict the conversion from 
MCI to AD [87]. SNAP-25 may even have relevance as 
a blood biomarker. Agliardi et al. showed that SNAP-25 
can be detected in serum, where it appears in neuron-
derived plasma exosomes, which are extracellular vesicles 
involved in intercellular communication. Serum levels of 
SNAP-25 are lower in AD patients compared to healthy 
controls [88]. Although further studies are needed, these 
findings indicate the potential use of SNAP-25 as a pre-
synaptic injury-related biomarker.
Synaptotagmin-1 was one of the first proteins detected 
in the CSF of early-onset AD patients [89]. Synaptotag-
min-1 is a pre-synaptic vesicle protein involved in the 
maintenance of correct synaptic transmission and cog-
nitive function. Recent studies reported increased CSF 
Synaptotagmin-1 levels in both MCI and AD patients 
compared to healthy controls [90], indicating that Synap-
totagmin-1 is a potential CSF biomarker of both AD and 
conversion from MCI to AD.
Neurogranin (Ng) is a post-synaptic protein that regu-
lates calcium signaling and synaptic plasticity mainly 
found in the dendritic spines of the amygdala, hippocam-
pus, and caudoputamen [29, 82]. High CSF Ng levels have 
been reported to predict future cognitive decline specific 
to AD pathogenesis, with better specificity than p-tau 
[91]. Furthermore, several studies have shown elevated 
CSF Ng levels in MCI and prodromal AD patients [91, 
92]. Interestingly, a recent study carried out by Kirsebom 
et al. identified an elevated CSF Ng/BACE1 ratio as a pre-
dictor of very early cognitive decline in AD. Specifically, 
elevated Ng/BACE1 is associated with lower hippocam-
pal and amygdala volumes of MCI patients compared to 
healthy controls [93]. All these findings highlight Ng as 
one of the most relevant biomarkers related for synaptic 
dysfunction in AD. The scientific evidence to date has 
not clarified the predictive value of blood Ng as an AD 
synaptic-damage biomarker. In addition, further studies 
are needed to define the specific range of Ng values for 
diagnoses of different stages of AD.
BBB dysfunction‑related biomarkers
Cerebrovascular disease and AD share multiple risk fac-
tors. Substantial evidence suggests that vascular dysfunc-
tion is the earliest event in the pathogenic development 
of late-onset AD [94]. Vascular dysfunction, associated 
with aging, causes reduced oxygen, glucose, and nutri-
ent supply to the brain, which directly damages not only 
the parenchymal cells, but also the BBB structure. This in 
turn promotes the overproduction of ROS, nitric oxide, 
and inflammatory cytokines in response to the neuro-
toxic effects of vascular dysfunction, which contributes to 
a vicious circle of global neurotoxicity affecting both BBB 
dysfunction and AD pathogenesis [94]. The standard bio-
marker of BBB dysfunction measured in clinical practice 
is the CSF/serum ratio of albumin [95]. Although the role 
of albumin and its predictive value are still controversial, 
many efforts have been made to exploit the usefulness 
of this biomarker. Other molecules have also emerged 
as potential biomarkers of BBB-dysfunction, such as 
VCAM-1, ICAM-1, MMPs, VEGF, PIGF, sPDGFR-β, and 
tight junction proteins (such as claudins and occludin) 
[25, 29]. However, further studies are needed to deter-
mine their predictive value in CSF, as well as their cor-
relation in peripheral blood.
Lipid metabolism‑related biomarkers
Brain tissue is highly enriched in lipids. Lipid metabolism 
is decisive for the synaptic activity, neuronal survival, and 
immune responses of glial cells, and AD pathogenesis is 
accompanied by continuous changes in brain lipid pat-
terns [96]. Thus, proteins related to lipid transport and 
metabolism in the CNS have been proposed as poten-
tial biomarkers of AD pathogenesis. Undoubtedly, ApoE 
is the prototypical protein involved in lipid homeostasis 
and AD development. The expression of the ApoE ɛ4 
allele is well known as the strongest genetic risk factor 
for AD [27, 97]. Therefore, CSF ApoE levels have been 
investigated as AD progression biomarkers and for the 
differential diagnosis of AD and other neurodegenera-
tive disorders [27]. However, further studies are needed 
to validate its potential predictive value in blood sam-
ples. Similarly, heart fatty acid-binding protein (FABP3), 
ApoH, and vitamin D-binding protein are related to 
lipid metabolism and increased levels of them have been 
found in the CSF of AD patients. Moreover, these have 
been proposed for the differential diagnosis of AD from 
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Lewy body dementia, Parkinson’s disease, and other 
dementias [27].
Neurotoxins clearance‑related biomarkers
The clearance of toxic metabolites from the brain is 
essential for healthy function. Since the dysregula-
tion of clearance mechanisms has been identified as a 
direct cause of AD development, proteins related to the 
removal of cerebral metabolic waste, Aβ and p-tau pep-
tides, and reactive oxidative species have been suggested 
as candidate biomarkers [27, 98]. Clusterin, Orexin and 
Transthyretin, which are involved in the clearance of par-
tially unfolded proteins and Aβ peptides, have thus been 
described as potential biomarkers [27]. Interestingly, 
clusterin, also called APOJ, is also related to lipid trans-
port, inflammation, and chaperone activities. Similarly, 
LAMP-1, carboxypeptidase E, cystatin C, and ubiqui-
tin CSF levels are increased in patients with AD and are 
emerging as potential neurotoxin clearance-related bio-
markers [27, 99].
Metal ion homeostasis‑related biomarkers
Metal ions have been widely described as potential tar-
gets for the diagnosis and treatment of AD. The abnormal 
accumulation of metal ions, like zinc, copper, and iron, 
in the brain has been closely related to the overproduc-
tion of Aβ peptide and p-tau, and the accumulation of 
senile plaques and NFTs [100]. Likewise, abnormalities in 
metal-binding proteins are a key factor in promoting the 
erroneous distribution and deposition of metal ions in 
the brain [100]. Some of the mechanisms by which metal 
ions promote these abnormalities are the induction of 
oxidative stress, autophagy dysfunctions, the disruption 
of endoplasmic reticulum and mitochondria structures, 
activation of β- or γ-secretases, inhibition of α-secretase, 
and activation of protein kinases such as cyclin-
dependent protein kinase-5 (CDK5), glycogen synthase 
kinase-3β (GSK-3β), mitogen-activated protein kinases 
(MAPKs), etc. [100]. Moreover, all these alterations 
enhance the abnormal brain deposition of metal ions and 
further dysregulate their homeostasis. Therefore, these 
metal ions have been proposed as potential biomarkers 
for tracking AD progression. Likewise, adjusting metal 
balance may be a potential treatment for AD pathologies 
and is a promising path for future research.
Molecular strategies for the therapeutic approach 
to Alzheimer’s disease
Amyloid‑β strategies
As explained above, the overproduction and accumula-
tion of Aβ lead to several neuropathological processes 
that trigger neuronal death, which translates into the 
memory loss and cognitive disorders typical of this 
disease [28, 101]. α-secretase is the main enzyme in amy-
loid-precursor protein (APP) metabolism and its action 
is followed by that of γ-secretase in physiological condi-
tions. Amyloidogenic processing occurs when an alter-
nate enzyme, β-secretase, acts instead of α-secretase 
[102]. Generally, Aβ-based therapies target several 
aspects of APP metabolism [101]. Likewise, Aβ-binding 
to several receptors has been related with some of its 
neurotoxic mechanisms (Table  1) [103]. Thus, thera-
peutic targeting to these proteins has been proposed to 
decrease amyloidogenic APP processing and Aβ-related 
toxicity.
In this context, recent pre-clinical studies have sug-
gested that epigallocatechin-gallate (EGCG), the most 
abundant polyphenol in green tea, induces α-secretase 
activity and improves non-amyloidogenic APP pro-
cessing [104]. Likewise, the effect of a one-year treat-
ment with EGCG on cognitive Aβ biomarkers, as well as 
metabolomics, microbiota, saliva, plasma, and urine, is 
being evaluated in a randomized, double-blind clinical 
trial in 200 subjects (NCT03978052) This study aims to 
demonstrate the potential prevention of cognitive decline 
in patients with positive ApoEε4 with subjective cogni-
tive decline after a multimodal intervention with EGCG 
[105]. The estimated study completion date is September 
2021, when the first results will reveal the potential of 
this drug for AD.
Etazolate is another compound that has been shown to 
possess neuroprotective effects in AD. It is a pyrazolopyr-
idine with anxiolytic-like properties that selectively mod-
ulates the  GABAA receptor. Marcade et al. demonstrated 
that Etazolate also promotes neuroprotection via the 
α-secretase pathway, leading to an induction of sAPPα, 
which is a neurotrophic and precognitive molecule [106]. 
Thus, modulators of the  GABAA receptors could offer a 
promising opportunity for the treatment of AD.
The active enantiomer of phenserine, which directly 
decreases levels of APP by interacting with APP 
mRNA, has also been found to be effective in enhanc-
ing α-secretase and AChE activity [4]. However, other 
secretase-targeting drugs have not succeeded. For 
instance, tarenflurbil, the active enantiomer of flurbi-
profen, ELND006 and Semagacestat are all γ-secretase 
inhibitors developed to reduce Aβ levels that failed in 
clinical trials because of their significant adverse effects, 
and the absence of results extrapolatable from pre-clini-
cal models to patients [4].
Modulating Aβ transport is another therapeutic 
approach to AD. Apolipoproteins have an important 
role in Aβ transport and metabolism since they regu-
late the movement of Aβ peptides between the periph-
ery and CNS. ApoEε4 increases the passage of Aβ from 
blood to the brain through the low-density lipoprotein 
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Table 1 Main receptors and their implications in Aβ binding‑mediated neurotoxic effects [103]
Receptor Localization Proposed mechanisms
NMDAR Postsynaptically located on dendrites and dendritic spines Impairment of NMDAR activity: removal from the cell surface and 
triggering of synaptic depression signalling pathways
Increase of NMDAR function: AβOs induce neuronal oxidative stress 
through an NMDAR‑dependent mechanism
AβOs bind to NMDAR →excessive activation of NMDAR →inflow of 
 Ca2+ to neurons →excitotoxicity
AMPAR Hippocampal pyramidal neurons and dendritic spines AβOs → synaptic dysfunction by inducing calcineurin‑dependent 
internalization of AMPAR
PrPC Brain neurons and spinal cord Initial interaction of AβOs with PrPC on the neuronal surface which 
leads to:
Disturbed regulation of BACE1 activity
Inhibition of elongation of Aβ fibrils
Intracellular  Ca2+ increase in neurons via the complex PrPC‑
mGluR5 →impairment of synaptic plasticity
mGluR5 Hypothalamus and cortex Complexes of AβOs with PrPC generate mGluR5‑mediated influx of 
 Ca2+ in neurons → excitotoxicity
AβO‑PrPC‑mGluR5 complexes signalling pathway involved in den‑
dritic spine loss
β2ARs Locus coeruleus, hippocampus and cortex AβOs induce the degradation of β2ARs, which leads to:
Enhanced γ‑secretase activity → Aβ plaque formation
Reduction of neurogenesis
Reduction of the levels of synapse‑associated proteins such as synap‑
tophysin, synapsin 1, and PSD‑95
α7nAChR Septo‑hippocampal region and cortical neurons Aβ42 binds to α7nAChR → loss of cholinergic neurons in the 
brain → receptor internalization and intracellular accumulation of 
Aβ
IR Choroid plexus, olfactory bulb and regions of the striatum and 
cerebral cortex
AβOs bind to neuronal IR → impaired insulin signalling and brain 
insulin resistance → elevated Aβ production and reduced AβO 
clearance → Aβ deposits in the brain → neuronal damage
p75NTR White matter brain regions and spinal cord AβOs bind to membrane p75NTR → formation of annular amyloid 
pores and ion channels → induction of aberrant cytoskeletal 
changes in dendritic spines
AβOs bind to IGF‑1R → phosphorylation of IGF‑1R → induced 
p75NTR expression → cell death by fibrillary form of Aβ
ILR Hippocampus and surface of B lymphocytes, dendritic cells, natural 
killer cells, macrophages, granulocytes, mast cells, etc
AβOs bind to PirB → impartment of synaptic plasticity → disruption 
of hippocampal long‑term potentiation → Aβ‑induced deficits of 
memory
AβOs bind to FcγRIIb → AβO‑induced inhibition of long‑term poten‑
tiation → Aβ‑mediated neuronal dysfunction
TREM2 Surface of immune cells of myeloid origin AD‑associated TREM2 mutations → reduction of AβOs binding and 
degradation of Aβ → microglial depolarization, induction of  K+ 
current into cells as well as increased cytokine expression and 
secretion, cells migration, proliferation, apoptosis, and morphologi‑
cal changes of microglia
Eph4A
EphB2
Hippocampal neurons AβOs reduce Eph receptor expression, promote its endocytosis and 
its degradation in the proteasome, which leads to:
Loss of dendritic spine
Synaptic dysfunction
Increase of synaptoneurosomes
Impairment of NMDAR functioning and cognitive deficits
RAGE Blood–brain barrier Expression of RAGE is increased in the AD brain → RAGE is responsi‑
ble of Aβ influx from plasma to BBB → increase of free Aβ fraction 
in plasma
LPR2 Choroid plexus epithelium and ependymal cells covering the brain 
ventricles
Aβ alone did not bind directly to LRP‑2, whereas complexes of Aβ‑40 
with ApoJ are able to react with LRP‑2 → clearance of Aβ
VDR Broadly expressed in all brain regions 1,25‑(OH)2D3 binds to VDR → increase the expression of amyloid 
transporters (i.e. LRP‑1) → increase of transport of Aβ across the 
BBB → Aβ clearance
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receptor-related protein (LRP) [107, 108]. The periph-
eral administration of soluble LRP has been proposed 
as a promising treatment for AD by increasing Aβ efflux 
from the brain to peripheral blood [109]. Similarly, 
increasing the Aβ clearance has been studied as a thera-
peutic option for AD. Some proteases, such as metallo-
proteinase 9, neprilysin, and insulin-degrading enzyme, 
can degrade Aβ plaques. The levels of these enzymes 
decline in AD and this could contribute to Aβ accumula-
tion and senile plaque formation. The activation of these 
types of enzymes has also been proposed as a therapeutic 
approach to AD [109].
Therapeutically decreasing Aβ aggregation is one of 
the most explored routes to interfere clinically with AD 
progression. Drugs like tramiprosate, EGCG, ELND005, 
and melatonin have been studied in pre-clinical and clini-
cal trials because of their demonstrated inhibition of the 
aggregation of Aβ peptides and dissolution of pre-formed 
fibrils [4]. Likewise, the use of monoclonal antibodies 
against Aβ aggregation has been explored. For instance, 
aducanumab has been shown to enter the brain, bind 
parenchymal Aβ, and reduce soluble and insoluble Aβ 
in a dose-dependent manner in both transgenic mouse 
models and patients with prodromal or mild AD [110]. 
Aducanumab is currently being investigated in a phase III 
clinical trial (NCT01677572) that is expected to provide 
compelling support for the amyloid hypothesis. How-
ever, the FDA’s advisory committee recently expressed 
concern about the biostatistical and neurologic results of 
this trial. Moreover, experts agreed that the aducanumab 
efficacy data were weak and pointed to inconsistencies in 
the data that came from two futility-stopped Phase 3 tri-
als and one Phase 1b trial. Thus, the committee deemed 
the evidence premature for approval and recommended a 
confirmatory trial. The decision now rests with the FDA, 
which is predicted to decide by June 2021 [111].
Boada et  al. investigated the effects of plasmapher-
esis with albumin replacement, plus intravenous immu-
noglobulin and obtained promising results in terms 
of disease progression in a multicenter, randomized, 
blinded and placebo-controlled, parallel-group, phase 
IIb/III clinical trial (AMBAR) of mild-to-moderate AD 
patients (NCT01561053) [112, 113]. The molecular basis 
of this innovative therapeutic approach was the uptake 
and clearance of blood Aβ by replaced albumin, thereby 
promoting the transport of Aβ peptides from CSF to 
plasma, which in turn reduces the Aβ burden by restor-
ing the normal balance of Aβ between brain and blood. 
The trial obtained promising results in terms of disease 
progression, indicating that this approach is an important 
development in AD therapeutics [114].
Tau‑based strategies
Targeting AD as a tauopathy is another main therapeutic 
approach. Soluble tau is found in neuronal cells and plays 
a dominant role in axonal growth and neuronal develop-
ment [115]. Its importance lies in its role in regulating 
and stabilizing microtubules, essential structures of the 
cell cytoskeleton. While under physiological conditions, 
the phosphorylation and de-phosphorylation of tau are 
in equilibrium, thus maintaining its ability to bind to 
microtubules; in pathological situations, its hyperphos-
phorylation generates insoluble filaments in the form of 
tangles, which leads to synaptic dysfunction and neu-
ronal degeneration [115]. Several studies have also shown 
a relationship between the amyloidogenic pathway and 
tau, demonstrating that the acceleration of tau hyper-
phosphorylation is promoted by soluble Aβ oligomers 
and, in turn, p-tau enhances the formation and aggrega-
tion of Aβ plaques [116].
Therefore, targeting tau phosphorylation is another 
important strategy in AD therapeutics, in particular the 
inhibition of tau protein kinases to prevent tau phos-
phorylation and the concomitant microtubule instabil-
ity. Of the tau protein kinases, glycogen synthase kinase 
3 (GSK3) has possibly aroused the most interest [117]. 
Specifically, valproate, lithium, tideglusib, caffeine, 
and several other GSK3 inhibitors have been studied in 
AβOs, amyloid-β oligopeptides; α7nAChR, Acetylcholine Receptor; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; β2ARs, β2-Adrenergic 
Receptors; LPR2, lipoprotein-related protein 2; mGluR5, Metabotropic Glutamate Receptor 5; EphA4, EphB2, Tyrosine Kinase Ephrin Receptors; FcγRIIb, Fragment 
crystallizable gamma receptor II b; IGF-1R, insulin-like growth factor 1 receptor; ILR, Immunoglobulin-Like Receptors; IR, Insulin Receptor; NMDAR, N-methyl-D-
aspartate receptor; p75NTR, p75 Neurotrophin Receptor; PirB, paired immunoglobulin-like receptor B:  PrPC, Cellular Prion Protein; RAGE, Receptor for Advanced 
Glycation Endproducts; SIRT 1, Sirtuin 1; TREM2, Triggering Receptor Expressed on Myeloid Cells 2; VDR, vitamin D receptor
Table 1 (continued)
Receptor Localization Proposed mechanisms
SIRT1 Predominantly located in the nucleus, but also in the cytosol of 
neurons of the hippocampus and hypothalamus
SIRT1 deficiency has been described to be responsible for the 
increased risk of insulin resistance, obesity and diabetes, which in 
turn are risk factors of AD
SIRT1 deficiency has been described to be involve in the reduction of 
normal cognitive function and synaptic plasticity
Reduction of SIRT1 → reduction of α‑secretase activity → enhance‑
ment of amyloidogenic processing of APP
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pre-clinical and clinical trials as therapeutic candidates 
for AD tauopathy [4]. Similarly, the reduction of tau oli-
gomerization, prevention of microtubule stabilization, 
and enhancement of tau degradation are other strategies 
currently being studied to improve AD therapy manage-
ment [4].
Neurotransmission
The cholinergic system may be strongly affected in AD. 
Specifically, the degeneration of cholinergic neurons in 
the basal anterior brain has been reported to play a pre-
dominant role in the progression of the disease [118]. 
Much like tau hyperphosphorylation, cholinergic deficit 
is also related to Aβ. More than two decades ago, Pit-
tel et  al. showed the potentiation of the non-amyloido-
genic pathway by activating the cholinergic receptors of 
the cerebral cortex and cerebellum and the consequent 
decrease in Aβ formation [119].
The inhibition of acetylcholinesterase (AChE) causes an 
increase in acetylcholine in the synaptic space and, there-
fore, an increase in cholinergic activity. Indeed, three 
of the four marketed AD drugs are inhibitors of AChE, 
namely Donepezil, Rivastigmine and Galantamine. They 
were approved by the FDA between 1998 and 2001, and 
since their inception have been used in mild or moder-
ate phases of the disease [120]. However, these drugs 
have poor effectiveness, with patients continuing to show 
progressive cognitive impairment, suggesting that these 
compounds have only palliative effects. In contrast, their 
adverse effects, due to peripheral cholinergic hyperac-
tivity, reduce patients’ adherence to the treatments and 
therefore limit their success [120, 121].
AD neuronal pathogenesis also extends to the gluta-
matergic system, especially in later stages of the disease. 
At the central level, glutamate intervenes in most excita-
tory signals and participates in several physiological pro-
cesses, such as neurogenesis, synaptic plasticity, memory, 
and learning [122]. Glutamatergic excitotoxicity is due 
to a massive influx of  Ca2+ ions. In AD, this toxicity is 
mainly due to the overstimulation of NMDARs caused 
by deposits of Aβ and tau tangles. Likewise, the increase 
in Aβ levels induces a decrease in glutamate reuptake by 
glial cells, which translates into an increase in neuronal 
death [123]. Memantine, a non-competitive NMDAR 
antagonist, was approved for AD treatment in 2003 by 
the FDA and is used in moderate to severe phases. Like 
AChE inhibitors, it acts at a symptomatic level, reducing 
the neurotoxic effects caused by glutamatergic excito-
toxicity and improving memory and learning processes. 
Although its effectiveness is superior to that of AChE 
inhibitors, it does not stop the disease progress or resolve 
the pathogenesis of AD [4].
In terms of neurotransmission, other routes related to 
the development of AD have recently come into thera-
peutic focus, particularly the GABAergic system, the 
serotonin receptor, and the modulation of histaminergic 
and adenosine receptors [4]. However, further research is 
needed to clarify the roles of these systems in AD.
Oxidative stress
Oxidative stress crucially drives many disorders, espe-
cially those inherent to the CNS, where there is very high 
oxygen consumption but normally low concentrations 
of antioxidant enzymes [124]. In 2001, Nunomura et  al. 
reported the level of oxidative stress in the early stages 
of AD [125]. Unexpectedly, oxidative damage decreases 
with disease progression and the formation of senile 
plaque and tau tangles, suggesting the existence of com-
pensatory mechanisms. Some researchers have suggested 
that the appearance of both senile plaque and tau tangles 
is enhanced with increasing oxidative stress. However, 
other authors have claimed that the participation of Aβ 
in the deregulation of the intracellular homeostasis of 
 Ca2+ and different mitochondrial mechanisms instead 
lead to the appearance of oxidative processes [124].
There is inconsistent evidence about the effect of exog-
enous antioxidants such as vitamins, carotenoids, phy-
tochemicals, and synthetic compounds against already 
established oxidative stress damage. However, rutin, cur-
cumin, and melatonin, potent antioxidant compounds, 
have been shown to possess several beneficial roles apart 
from their powerful antioxidant effects, such as amyloid-
disaggregating properties and anti-inflammatory activity 
[126]. Likewise, boosting endogenous antioxidant activ-
ity is another strategy for the oxidative stress approach 
to AD. The nuclear factor 2 (Nrf2) /antioxidant response 
element (ARE) cascade is the primary endogenous anti-
oxidant pathway. The translocation of Nrf2 from the 
cytosol into the nucleus is blocked in AD. Thus, drugs 
inducing the Nrf2/ARE pathway could be an interesting 
approach for the treatment of AD [4].
Neuroinflammation
Neuroinflammation is the physiological response of the 
CNS immune system against molecular alterations in 
the brain tissue. Growing evidence suggests that the 
pathogenesis of AD is not restricted to neurons, but 
also involves immunity in the brain [66]. Thus, the acti-
vation of astrocytes and microglia, resident immune 
cells of the CNS, is a hallmark of neuroinflammation 
that is observed in most neurodegenerative conditions, 
including AD [127]. However, the underlying molecular 
mechanisms remain unclear. In general, the activation 
of glial cells induces many biochemical and cytological 
changes, such as the production of ROS, the secretion of 
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proinflammatory cytokines, and the degradation of neu-
roprotective retinoids, thus endangering the surround-
ing healthy neurons. Similarly, external factors, such as 
systemic inflammation and obesity, likely interfere with 
immune processes in the brain and further promote dis-
ease progression [65]. Glial cells, mainly composed of 
astroglia, microglia, and oligodendroglia, become acti-
vated and adopt different gene expression profiles in 
pathological conditions, which leads to a neuroinflam-
matory response [128]. This response causes an overpro-
duction of pro-inflammatory cytokines, which gives rise 
to an increase of amyloidosis state, looser maintenance 
of the myelin that surrounds CNS axons, an increase of 
ROS, mitochondrial damage, and ER stress, among other 
effects. Neuroinflammation finally contributes to the 
neurotoxic processes that produce neuronal death in AD 
[128].
Epidemiological data show the protective effect of 
anti-inflammatory agents in neurodegenerative diseases. 
Thus, the hypothesis linking neuroinflammation to the 
pathogenesis of AD has gained strength in recent years, 
even suggesting that its onset occurs long before memory 
impairment becomes clinically evident [129]. This has 
also promoted studies of NSAIDs in AD pre-clinical and 
clinical trials. In the context of AD NSAIDs may not only 
inhibit cyclooxygenase, but also target α-secretase or 
maintain  Ca2+ homeostasis [4]. However, although epi-
demiological and observational studies have highlighted 
the beneficial effect of NSAIDs in reducing the symptoms 
and progression of AD, randomized clinical trials and 
meta-analyses have failed to corroborate this significantly 
[130].
Mitochondria damage approach
The implications of mitochondrial dysfunction, mainly 
caused by ROS overproduction have also recently been 
described in the pathogenesis of AD [131]. Controlling 
ROS production is considered even more promising than 
traditional antioxidant strategies, which only act against 
accumulated ROS. Some molecules that have been stud-
ied in terms of mitochondrial anti-oxidants are coenzyme 
Q10, L-carnitine, triphenylphosphonium, and lipoic acid 
[132]. The latter also increases acetylcholine production 
and down-regulates the expression of pro-inflammatory 
cytokines [133]. Dimebon, an anti-histaminic drug, was 
also evaluated for its activity towards mitochondria and 
shown to block mitochondrial permeability transition 
pore opening, which translates to protection against 
cellular dysfunction and apoptosis processes [134]. 
However, the clinical translation of mitochondrial thera-
peutics has not yet occurred [135] and further studies are 
needed to elucidate the specific role of mitochondria in 
AD development.
Metabolic alterations
In recent years, several studies have focused on clarifying 
the relationship between dementia and metabolic disor-
ders such as diabetes, obesity, dyslipidemia, and hyper-
tension. The alteration of the insulin pathway, a reduction 
in the expression of its receptors, an increase in free fatty 
acids and cholesterol, an increase in lipogenesis, and 
altered vascular function are some comorbidities related 
to the appearance of AD [7]. All these processes alter 
the clearance of Aβ in brain tissue, stimulate the hyper-
phosphorylation of tau, promote astrocyte and micro-
glia activation and the secretion of ROS, and, ultimately, 
exacerbate the signs and symptoms of AD [136]. This 
highlights the importance of addressing both disorders 
as a single entity and the need to elucidate the underly-
ing molecular connections to clarify the relationship 
between them and, therefore, their etiology. Thus, statins 
or antidiabetic drugs are emerging as potential, promis-
ing therapeutic candidates in AD management [137, 138].
Controlled drug delivery systems
Until the mid-twentieth century, the most common 
pharmaceutical formulations were tablets, capsules, and 
syrups. These types of formulations meant an average 
of 3–4 administrations per day for patients. Likewise, 
many drugs with limited solubility and bioavailability had 
restricted use in the clinic, regardless of the therapeutic 
potential of the active molecule. Controlled drug delivery 
systems address many of these obstacles.
In 1952, Smith Klein Beecham designed the first con-
trolled release system (CRS) called “Spansule® technol-
ogy” [139]. This resulted in the first generation (1G) of 
CRS, which focused on the control of release kinetics. 
Until the 1980s, 1G CRS were most productive, with a 
large number of new formulations with easy adminis-
tration (mainly oral and transdermal routes) [140]. The 
second generation (2G) focused on developing more 
advanced systems, such as CRS of intelligent poly-
mers sensitive to the environment, zero-order releases, 
depot formulations aimed at very long administrations 
(months) or hydrogels. This generation was not as pro-
ductive as the 1G in terms of the number of formulations 
that entered into clinical practice, due to the complexity 
of development presented by these new systems [139].
It was not until 2010 that the third generation of CRS 
(3G) emerged. 3G CRS comprise present and future 
developments to improve the clinical problems noted 
with 2G CRS. Efforts have focused on developing CRS 
with more predictable kinetics through in vitro methods, 
selective releases, such as longer-lasting systems and easy 
administration, and, overcoming the physicochemical 
and biological barriers that were not breached by 2G CRS 
[140]. Currently, the use of different nanocarriers is one 
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of the most widely used state-of-the-art technologies to 
overcome the disadvantages of available drugs and offer 
new theragnostic approaches, especially in those diseases 
whose affected organs are difficult to access, such as AD.
The main properties that a device should possess to be 
a CRS are: (i) release the drug at a predetermined rate; (ii) 
can be administered locally or systemically; (iii) remain in 
the body for a specified period of time; (iv) target the car-
ried drug to the specific site of action [141]. In addition, 
due to Fick’s law, diffusion is the mechanism that governs 
the controlled release of a drug and depends on the aque-
ous solubility, ionization, PKa, stability, partition coeffi-
cient, and molecular weight of the drug [141].
The general classification of CRS is based on the mech-
anisms that govern the release process and the entrap-
ment of the drug [142]. Thus, the main types of CRS are: 
(i) diffusion-controlled CRS, which act as reservoirs and 
monolithic systems; (ii) water penetration-controlled 
CRS, where osmotic and swelling processes control the 
release of the drug; (iii) chemically-controlled CRS, 
which can be designed as biodegradable reservoirs and 
monolithic systems or biodegradable polymer backbones 
with pendant drugs, where the release ratio is man-
aged by chemical reactions between the device and the 
medium; (iv) responsive CRS, which act as physically or 
chemically responsive systems, mechanical-, magnetic-, 
or ultrasound-responsive systems, and biochemically-
responsive self-regulated systems; (v) particulate CRS, 
which can be designed as microparticles, liposome sys-
tems, and polymer-drug conjugates, among others [142].
The most important CRS developed for nanomedicine 
applications are liposomes, micelles, nanoparticles, car-
bon nanotubes, graphene sheets, hydrogels, dendrimers, 
polyelectrolyte complex, and quantum dots. Table 2 sum-
marizes the main characteristics of all CRS developed for 
biomedical applications [141, 142].
Nanotechnologic strategies for Alzheimer’s disease
Nanocarriers as diagnostic tools in AD
One of the main problems of AD is its late diagnosis due 
to the delayed manifestation of first clinical symptoms 
compared to the onset of its molecular and cellular mani-
festation in the brain. When the first symptoms appear, 
the neuronal damage is already established and irreversi-
ble. Therefore, devices that can recognize AD biomarkers 
in the early stages preceding memory loss and cognitive 
decline have attracted much interest in clinical research. 
Historically, the first clinical biomarker of AD was the Aβ 
peptide of senile plaques, which accumulates in the gray 
matter of AD brains. Thus, nanodevices specific for Aβ 
have been designed for diagnostic purposes [143].
In this context, superparamagnetic iron oxide nanopar-
ticles (SPIONs) used with magnetic resonance imaging 
(MRI) were the first attempt to use this technology for 
AD diagnosis. This type of nanovehicle, which could be 
surface modified with specific antibodies to recognize 
AD biomarkers, has shown elevated targeting in in vitro, 
in  vivo, and ex  vivo AD models. Thus, SPIONs coated 
with ganglioside carbohydrate (sialic acid), Aβ1-42 anti-
body, and curcumin are MRI agents used to identify Aβ 
plaques [144, 145]. Similarly, enhanced diagnosis was 
provided by liposomes modified with gadolinium and 
ET6-21, an amyloid-targeting ligand, compared to con-
ventional MRI in an in vivo model of AD [146]. The pre-
ferred administration route for these kinds of diagnostic 
nanocarriers is intranasal since it is non-invasive, allows 
penetration across the BBB, and avoids systemic adverse 
effects. A hybrid surface-modified graphene oxide with 
both tau and Aβ antibodies linked to magnetic core–
plasmonic coat nanomaterials was also developed. This 
nanodevice readily detected Aβ and tau proteins in an 
in vitro model of AD [143].
Another diagnostic application of nanocarriers is the 
specific binding of disease-specific proteins. As explained 
above, CFS and plasma show some of the molecular 
alterations that occur in the brain parenchyma of AD 
patients, with levels of Aβ peptides, tau, NfL, and SNAP-
25, among others, increased in both. Nanocarriers could 
act as uptake tools to monitor these biomarkers, thus 
contributing to a solid diagnosis of the stage and severity 
of AD pathogenesis [143].
Nanocarriers as therapeutic tools in AD
The complexity of the therapeutic approach to AD lies 
not only in its unknown etiology and the lack of available 
effective treatments, but also in the restricted access to 
the affected organ. Three biological barriers control the 
passage of most substances into the brain and thus sig-
nificantly limit drug access: the BBB, blood-CSF barrier 
(BCSFB), and ependymal barrier [143]. For orally admin-
istered drugs, the gastrointestinal barrier and hepatic 
first-pass effect must also be added [147]. Likewise, clear-
ance mechanisms and efflux pumps significantly reduce 
the half-life of drugs in the body, thereby contributing to 
the reduction of pharmacological effectiveness [148].
Apart from accessibility problems, drugs administered 
to the CNS, as well as other organs, must fulfill specific 
biopharmaceutical characteristics that confer high bio-
availability, but these are not always present. Although 
their pharmacological activity might be relevant, many 
drugs have physicochemical disadvantages, such as low 
solubility, short stability, and high molecular weight, that 
significantly reduce their bioavailability and, therefore, 
their final therapeutic effectiveness [149]. Additional 
challenges that CNS therapies face include the presence 
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of peripheral adverse effects and the difficulty of finding 
the therapeutic threshold and maintaining it over time.
To overcome all these obstacles, the therapeutic poten-
tial of drug-loaded nanocarriers in different neurode-
generative diseases has been explored [150]. The high 
surface-to-volume ratio of nanocarriers and the possibil-
ity of surface functionalization with desired ligands are 
the two main exploited characteristics of these devices 
for drug delivery to CNS [150]. In addition, Aβ target-
ing has been the main objective of nanomedicine to date. 
Three methods from nanotechnology have been used to 
target and modify senile plaques: (i) genetic regulation 
and/or inhibition of the synthesis of Aβ peptide; (ii) inhi-
bition and/or delay of the Aβ nucleation dependent pro-
cess; (iii) clearance of already-formed Aβ plaques [143]. 
Álvarez-Erviti et  al. employed naturally inert exosome 
nanocarriers to deliver BACE1-siRNA into the brain 
and silence BACE expression, thus inhibiting the cleav-
age of APP and, in turn, the overproduction of Aβ pep-
tide [151]. Recent findings related to the most common 
nanovehicles in preclinical assays of AD are described in 
depth below.
Lipid‑based nanoparticles for Alzheimer’s disease
Lipid-based NPs (LNPs) are among the most used con-
trolled drug delivery systems to target and deliver drugs 
to the brain. Their safety, biocompatibility, and biodeg-
radability make these systems an interesting choice for 
drug nanocarriers. Furthermore, since their inherent 
lipidic structure is similar to the lipid composition of 
the BBB, their penetration into the brain by the transcel-
lular pathway is favored [152]. The core of LPNs is com-
monly composed of monoglycerides, triglycerides, fatty 
acids, fatty alcohols, mixtures and waxes [153]. The most 
common LNPs are liposomes, solid lipid NPs (SLN), 
and nanostructured lipid carriers (NLCs), which mainly 
differ in the disposition of the lipid layers, morphology, 
loading capacity, average particle size, and electrokinetic 
behavior [154]. This type of nanocarrier can encapsu-
late both hydrophilic and hydrophobic drugs, which sig-
nificantly increases their versatility [155]. However, their 
low stability, complex fabrication method, unexpected 
polymorphic transitions, and drug release during storage 
are some disadvantages that complicate large-scale pro-
duction and, therefore, widespread use [154]. However, 
many efforts are being made to improve these issues and 
the potential of LNPs as diagnostic and therapeutic tools 
in AD and other CNS diseases [156]. Recent preclinical 
studies have produced interesting results by combining 
state-of-the-art LNPs and AD animal models (Table 3).
Almuhayawi et  al. designed pomegranate extract-
loaded LNPs to evaluate their effects in an aluminum 
chloride-induced rat model of AD [157]. Pomegranate 
extract is highly enriched in alkaloids and tannins, which 
have powerful antioxidant effects. The results showed 
that, compared to untreated controls, animals treated 
with such LNPs exhibited decreased NFTs and Aβ depos-
its, improved cognitive test scores, and increased bio-
markers of antioxidant activity in the brain homogenates. 
Similarly, Giacomeli et  al. investigated the neuroprotec-
tive effects of curcumin-loaded LNPs in a mice model 
of AD [158]. The therapeutic potential of curcumin has 
been widely recognized for many diseases, but its low 
solubility and, consequently, reduced bioavailability limit 
its pharmacological effect [159]. In this study, the authors 
developed a hybrid nanocarrier of a lipidic core with 
a PLC coat to confer better solubility. Animals treated 
with this nanocarrier showed improved spatial memory 
and reduced neuroinflammation biomarker levels in 
serum and the hippocampus and cortex homogenates. 
Pinheiro et  al. combined natural products and LNPs. 
The bioactive load was quercetin, a flavonoid present 
in many vegetables and fruits with strong antioxidant 
activity. The authors went one step further and coated 
the LNPs with transferrin to enhance transport across 
the BBB [160]. These LNPs were found to be non-toxic 
for hCMEC/D3 cells, a frequently used in vitro model of 
human BBB, and to enhance the penetration of quercetin 
through the BBB. Moreover, these LNPs inhibited Aβ1-
42 fibril formation in an in vitro model [161]. Similarly, 
α-bisabolol, a sesquiterpene alcohol found in Matricaria 
chamomilla essential oil with demonstrated anti-plasmo-
dial, anti-microbial, anti-inflammatory, anti-cancer and 
anti-cholinesterase properties, has significantly reduced 
bioavailability due to low solubility [162]. Sathya et  al. 
developed α-bisabolol-loaded Cholesterol LNPs and 
explored their neuroprotective effects in an Aβ-induced 
in  vitro model of Neuro-2a cells, a fast growing mouse 
neuroblastoma cell line [163, 164]. These studies show 
that such LNPs possess antioxidant potential, signifi-
cantly reduce β-secretase, caspase-3, and cholinesterase 
activities, inhibit Aβ aggregation, and protect Neuro-
2a cells from Aβ-induced neurotoxicity by reducing the 
expression of Bax and inducing the expression of Bcl-2 
proteins [163, 164].
Finally, Dara et al. recently investigated the therapeutic 
potential of erythropoietin (EPO) in AD. EPO is neuro-
protective in several diseases, such as spinal cord injury, 
cerebral ischemia, epilepsy, and diabetic neuropathy 
[165]. Moreover, EPO contributes to neuronal survival 
and the regulation of neurogenesis in both Parkinson’s 
disease and AD [166, 167]. However, EPO has restricted 
penetration through the BBB due to its hydrophilicity, 
rapid clearance from the bloodstream, and high molec-
ular weight. Encapsulated in SLNs, EPO reduced oxida-
tive stress and Aβ deposition in the hippocampus more 
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efficiently in an Aβ42-induced Wistar rat model of AD 
[165]. Moreover, animals treated with EPO-LNPs exhib-
ited increased spatial memory compared to free EPO-
treated littermates.
Polymeric‑based nanoparticles for Alzheimer’s 
disease
Due to their versatility and ease of fabrication by differ-
ent methods, polymeric NPs (PNPs) are among the most 
used carriers in nanomedicine applications [168, 169]. 
Their mean average size is between 10 and 1000 nm and 
they can load high amounts of both hydrosoluble and 
hydrophobic drugs [170]. Depending on the polymer 
composition, which can be natural or synthetic, PNPs 
can have both positive and negative surface charges. This 
characteristic significantly conditions their biological 
behavior, muco-adhesiveness, and penetration [171].
PNPs can be formulated as nanocapsules and nano-
spheres. Nanocapsules possess a vesicular structure in 
which drugs are dissolved in a liquid core surrounded 
by the polymeric capsule. In contrast, nanospheres are 
composed of a polymeric matrix in which drugs are dis-
persed in the matrix gaps or adsorbed onto the sphere 
surface [172]. The polymers most used to manufacture 
PNPs are polylactide (PLA), poly(lactide-co-glycolide) 
(PLGA), chitosan, polyethyleneimine (PEI), and poly-ε-
caprolactone (PCL), all of which were approved by the 
FDA for biomedical applications twenty years ago [173]. 
These kinds of vehicles have many important advan-
tages, such as their high loading capacity, controlled drug 
release kinetics, surface modifications for brain target-
ing, safety, biodegradability, biocompatibility, and easy 
elimination [168]. However, these systems also have some 
disadvantages that limit their use, especially the need for 
organic solvents during their fabrication. Nevertheless, 
their pharmacological potential has encouraged many 
researchers to explore the potential of PNPs for the diag-
nosis and therapeutic management of different neuro-
degenerative diseases [150]. Table  4 summarizes recent 
advances on the preclinical evaluation of state-of-the-art 
PNPs in AD.
The lack of effective treatments for AD has led to an 
incessant search for new pharmacological alternatives. 
Among these alternatives, natural compounds are emerg-
ing as potential therapeutic drugs for several diseases, 
such as cancer, diabetes, and cardiovascular and neuro-
degenerative diseases, including AD. Thus, Dhas et  al. 
developed cationic biopolymer core/shell NPs loaded 
with lutein (LT), a natural dietary carotenoid mainly 
obtained from food such as green vegetables, eggs, and 
corn [174]. Although this molecule has shown promis-
ing beneficial effects, such as anti-inflammatory, anti-
oxidant, and anti-cancer activity, its reduced solubility 
and bioavailability have restricted its use in the food and 
pharmaceutical industries [175]. In this study, the authors 
demonstrated that the developed nanocarrier possesses 
the optimal physicochemical characteristics for suitable 
in vivo administration. The PNPs have good entrapment 
efficiency, sustained LT release, protection of LT integ-
rity, biocompatibility with brain cellular models, and effi-
cient passage through an in  vitro BBB [174]. Moreover, 
after intranasal administration in rats, LT-loaded PNPs 
accumulated in the brain and exhibited reduced toxicity 
and significant ROS scavenging activity [174]. Similarly, 
Sathya et al. evaluated the therapeutic potential of phytol-
loaded PNPs in the regulation of the expression of AD-
related genes and neuronal degeneration in both in vitro 
and in vivo models of AD [176]. As with LT, phytol is a 
natural compound with several pharmacological proper-
ties but poor solubility and low absorption, resulting in 
reduced bioavailability that limits its clinical use [177]. 
In the in vitro Neuro-2a cell model, phytol-loaded PNPs 
inhibit apoptosis-mediated cell death and cholinester-
ase activity. In a transgenic nematode AD model, these 
PNPs were found to increase chemotaxis and lifespan 
and reduce ROS production and Aβ deposition. Further-
more, PNP treatment upregulated a gene involved in the 
longevity of nematodes, downregulated the expression of 
several AD-associated genes, and reduced the expression 
of Aβ peptide at the protein level [176].
Cano et  al. also studied natural-compound-loaded 
PNPs for AD [178]. In this study, the selected molecule 
was EGCG (see also above), which has shown therapeutic 
activity in many diseases, such aas breast cancer, diabe-
tes mellitus, Down syndrome, and different neurodegen-
erative diseases, but its instability in water solutions and 
in  vivo administrations reduce its effectiveness [179]. 
Co-encapsulating EGCG into PEGylated PLGA NPs with 
ascorbic acid (AA) to prevent auto-oxidation produces a 
nanosystem with significantly enhanced EGCG integrity, 
which is correlated with improved EGCG effectiveness in 
a variety of biological assays relevant to AD [178]. EGCG/
AA PNPs readily cross the BBB both in vitro and in vivo. 
Moreover, compared to free EGCG, EGCG/AA NPs 
exhibit improved bioavailability and pharmacokinetic 
profile and, in an AD mouse model, improved memory 
learning processes, reduced cognitive decline, neuroin-
flammation, and Aβ plaque burden, and increased synap-
tic expression.
Taken together, these findings highlight the relevance 
of natural compounds as promising therapeutic strate-
gies in AD management. However, PNPs loaded with 
natural compounds have not only been studied as thera-
peutics, but also for diagnostic purposes. In this regard, 
Ahlschwede et  al. developed curcumin-loaded PLGA 
NPs functionalized with K16ApoE, a BBB penetration 
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peptide. The authors aimed to create an effective tool for 
detecting cerebrovascular Aβ and treating cerebral amy-
loid angiopathy, which is widely observed in AD devel-
opment [180]. Using a quartz crystal microbalance with 
dissipation monitoring technology, the authors found 
that developed PNPs effectively migrated from the blood 
flow to the vascular endothelium. As expected, K16ApoE 
coating significantly improved BBB transcytosis and pro-
vided specific MRI contrast to detect brain Aβ plaques. 
Moreover, K16ApoE-PNPs also showed specific targeting 
of vasculotropic DutchAβ40 peptide that accumulated in 
the cerebral vasculature. Despite this study’s innovations, 
in  vitro and in  vivo assays are still required to describe 
the therapeutic effects of curcumin-loaded K16ApoE-
PNPs on memory impairment, cognitive decline, and 
molecular alterations related to AD development. Liu 
et  al. used nanotechnology for diagnosis. The authors 
designed carbon dots (CDs) sensitized lanthanide infi-
nite coordination polymer (ICP) NPs and a PNPs-based 
ratiometric fluorescent probe mainly composed of CDs, 
Europium Nitrate (Eu(NO3)3), and  Cu2+ [181]. The detec-
tion technique was based on the competitive coordina-
tion interaction of  Cu2+ between the guest CDs and Aβ 
monomer. Briefly, in the absence of Aβ, the coordination 
interaction between CDs and  Cu2+ disrupts the antenna 
effect, leading to the fluorescence quenching of  Eu3+. 
When developed PNPs contact an Aβ-enriched sample, 
the stronger coordination between Aβ monomer and 
 Cu2+ restores the red fluorescence of  Eu3+, leading to 
the detection and quantification of Aβ peptide by fluo-
rescence. In this study, developed PNPs were exposed to 
CSF/brain tissue samples of AD rats. The authors showed 
that their method is highly sensitive for the in vivo analy-
sis of Aβ monomer, thereby demonstrating the utility of 
this ratiometric fluorescent probe.
Some endogenous substances have been also described 
as pharmacological tools for AD. In that sense, Jeon et al. 
explored the therapeutic potential of Vitamin D-binding 
protein (DBP) [182]. DBP is a glycoprotein that is highly 
expressed in a wide variety of cells and tissues and has 
been shown to play important roles in several physiologi-
cal processes. Likewise, several studies have highlighted 
that DBP levels are altered in the serum and CSF of AD 
patients and possess optimal properties for Aβ binding, 
and thus peripheral clearance [183, 184]. However, pre-
vious studies have shown that plasma DBP has a rela-
tively short half-life. Jeon et al. aimed to encapsulate DBP 
into PLGA matrices to prolong the presence of DBP in 
the bloodstream and evaluate their effectiveness in an 
Aβ-overexpressing mice model of AD. The developed 
nanocarrier inhibited the polymerization and accumula-
tion of Aβ in both in  vitro and in  vivo models, amelio-
rated Aβ-associated neuroinflammation and neuronal 
loss, and significantly reduced the cognitive impairment 
of treated transgenic mice.
Finally, Guo et  al. recently developed a PNP coated 
with both a BBB-penetrating ligand and a neuron-target-
ing ligand for carrying the neuroprotective peptide NAP. 
NAP has been shown to provide neuroprotective activity 
against NMDA receptors and Aβ-mediated excitotoxic-
ity by interacting with glial and neuronal tubulin, thereby 
promoting microtubule assembly and the protection 
of the neuronal cytoskeleton [185]. As explained above, 
the clinical application of NAP is restricted due to its 
enzymatic degradation, ineffective neuron targeting and 
reduced half-life in the bloodstream [185]. The encap-
sulation of NAP in the nanocarrier improved its stabil-
ity in vivo. Likewise, coating the PNP’s surface effectively 
increased the accumulation of developed NPs in brain 
neurons. The evaluation of its pharmacological proper-
ties highlighted that NAP-PNPs promote the alleviation 
of oxidative stress, microtubule disruption, the attenu-
ation of neuroinflammation, and the inhibition of tau 
aggregation and apoptosis processes. Likewise, a rescue 
of the memory deficits and spatial learning in AD mice 
was observed after PNP treatment. Moreover, treatment 
with these PNPs also prevented tau hyper-phosphoryla-
tion and restored axonal transport.
Metal‑based nanoparticles for Alzheimer’s disease
Metal-based NPs (MNPs) are the most relevant inorganic 
nanocarriers because of their widespread use in nano-
medicine applications [186]. These vehicles usually have 
an average size of 10 to 100  nm. Moreover, their high 
surface area allows for coating with different molecules 
(e.g., antibodies, genes, peptides), which lets them act 
as biosensors and targeting tools. MNPs are commonly 
fabricated with gold, silver, iron, zinc, and copper, all of 
which provide different properties to the final nanocar-
rier [187]. MNPs have demonstrated anti-microbial, anti-
cancer, anti-inflammatory, and anti-oxidant properties, 
among others [188].
Different methods are employed in the fabrication of 
MNPs, with top-down methods (e.g., mechanical mill-
ing, laser ablation, and ion sputtering) and bottom-up 
methods (e.g., solid-state methods, liquid-state synthe-
sis methods, gas-phase methods, and electrochemical 
deposition). Note that the selected fabrication method 
significantly conditions the final physicochemical prop-
erties, morphology, and long-term stability of MNPs 
[189]. Green synthesis methods, an emerging trend of 
nanotechnology, can overcome the toxicity problems, 
high cost, and reaction complications of conventional 
fabrication methods, so they have attracted much recent 
interest. Green chemistry incorporates novel techniques 
to reduce the health and environmental burdens of 
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conventional techniques. Some of the most used green 
synthesis methods involve biological methods with dif-
ferent microorganisms and their enzymes and using plant 
extracts. The main advantages of these novel techniques 
are reduced costs, ease of scaling up for large-scale pro-
duction, and the complete elimination of energy, high 
pressure and temperature, and toxic chemicals [190].
Much current research focuses on MNPs because 
of their multiple benefits and versatility for use in dis-
ease diagnosis and treatment, labeling optoelectronic 
recorded media, cosmetics, and sensor technology, 
among others [189]. In addition, the magnetic properties 
of some of these MNPs can be exploited to enhance the 
accumulation of these NPs in specific organs since they 
can be detected and manipulated by remote magnetic 
fields [191]. Table  5 displays relevant studies involving 
the latest smart MNPs and AD preclinical models.
Currently, using MNPs for diagnosis purposes is being 
widely studied. For example, da Silva et al. recently devel-
oped a highly sensitive AChE electrochemical biosen-
sor based on an electrode modified with iron oxide NPs 
and a deep eutectic solvent [192]. Enzyme-modified 
electrode sensors offer a powerful tool for real-time 
diagnostics that overcomes the drawbacks of traditional 
analytical approaches, such as time-consuming pro-
cesses, high cost for measurements, and the need for 
highly specialized staff [192]. Likewise, their capabil-
ity to promote the fast electron-transfer kinetics of iron 
oxide NPs means they had optimal properties for use 
in the developed biosensor. Da Silva et  al. immobilized 
AChE on a polymeric-based film pre-formed in modified 
electrodes, which was composed of iron oxide NPs and 
an acid eutectic dissolvent. They tested different acids to 
evaluate their influence on the rate of growth and elec-
trochemical properties of the polymer films and finally 
selected  HNO3. The authors used chronoamperometry 
to investigate the catalytic activity of the developed bio-
sensor for ACh detection. After exposing the biosensor 
to synthetic urine containing known concentrations of 
ACh, the authors recorded the typical current–time volt-
age curves and demonstrated that this MNPs-based bio-
sensor has high sensitivity, excellent reproducibility, and 
long-term stability, with significant recovery ratios. In a 
related study, Xing et  al. investigated the development 
of an electrochemical technique for detecting Aβ based 
on silver NPs aggregates as the redox reporters and a cel-
lular prion protein  (PrP95-110) as the bio-receptor [193]. 
The fundamentals of their technique are based on the 
oscillation of the electrochemical signal promoted by the 
interaction of Aβ with the  PrP95-110-MNPs. The specific 
binding of the Aβ oligomers to the PrP peptide blocks 
the aggregation of the MNPs’ main electro-transmitter, 
which decreases the electrochemical signal that can be 
detectable and quantifiable. The exposure of this nanode-
vice to both Aβ-enriched artificial CSF and the human 
serum of AD patients demonstrated that the developed 
detection method exhibits high sensitivity and specific-
ity and requires simple manipulation, less time expense, 
lower expenses, and lower detection limits than those 
achieved by previously reported methods.
The use of MNPs as therapeutic tools for AD is also 
important. For example, Liu et al. explored the therapeu-
tic potential of quercetin-modified gold–palladium NPs 
to promote the clearance of intracellular Aβ by autophagy 
induction and, consequently, reduce Aβ-induced neuro-
toxicity [194]. As explained above, quercetin is a potent 
natural antioxidant with limited ability to cross the BBB 
and easy elimination. Recent studies have shown that 
quercetin can accelerate the elimination of abnormal Aβ 
by enhancing the autophagy effect of brain cells [194]. 
Liu et  al. reported that the developed MNPs are not 
toxic in both in  vitro and in  vivo and effectively cross 
the in  vitro BBB. Furthermore, they increased intracel-
lular autophagy levels, promoted the degradation of 
autophagosomes, enhanced Aβ clearance in brain cell 
cultures, and reduced Aβ-induced cytotoxicity. Similarly, 
Gao et al. recently evaluated multi-targeted chondroitin 
sulfate /selenium MNPs and evaluated their protective 
effect against Aβ-induced neurotoxicity [195]. Chondroi-
tin sulfate is a glycosaminoglycan with several biologi-
cal functions, such as antioxidation, anti-inflammation, 
and neuroprotection. Moreover, chondroitin sulfate is 
involved in cell migration, neurogenesis, axon growth, 
synaptic plasticity, neuron regeneration, the inhibition of 
Aβ fibril formation, and the blocking of Aβ-induced cell 
apoptosis [196]. Also, selenium is a potent antioxidant 
that plays important roles in detoxification, the protec-
tion of the immune system, and the regulation of cellu-
lar redox homeostasis. Furthermore, it also inhibits the 
formation of Aβ plaques and degrades preformed Aβ 
fibers [197]. In this new study [195], Gao et al. obtained 
promising results. Their MNPs could reduce damage to 
the cytoskeleton and neuronal cells and oxidative stress, 
inhibit the aggregation of Aβ and protect cells from its 
neurotoxicity, and attenuate the hyperphosphorylation 
of tau protein. Sonawane et  al. also explored the effect 
of MNPs in Tau-related pathogenesis. The authors bio-
logically synthesized two different protein-capped 
MNPs, (i) iron oxide NPs and (ii) cadmium sulfide NPs, 
and evaluated their effectiveness in an in vitro model of 
AD [198]. The surface modification of these MNPs with 
proteins was performed to inhibit Tau protein aggrega-
tion. To complete the biological synthesis of these carri-
ers, two fungal species were used, Fusarium oxysporum 
and Verticillium sp. The composition and synthesis of 
both NPs were different: iron oxide NPs were synthesized 
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extracellularly by the fungal species with transient ferro-
magnetic properties and capped with hydrolytic proteins. 
In contrast, cadmium sulfide NPs were synthesized from 
the extracellular sulfate-reducing enzymes secreted by 
the fungus when provided with mixture of salts, so the 
surface proteins were composed of a mixture of four dif-
ferent proteins that probably belonged to the group of 
these sulfate-reducing enzymes. Both nanocarriers did 
not affect the viability of cultured cells. Furthermore, 
both MNPs efficiently inhibited Tau aggregation, and 
cadmium sulfide NPs exhibited a significant dissembling 
of Tau NFTs.
As described above, oxidative stress is one of the most 
important molecular hallmarks in AD development. In 
AD pathogenesis, the exacerbated formation of  H2O2 is 
favored by generalized brain oxidative stress. Metal che-
lators can block the detrimental effects of ROS, but their 
non-specific interactions with metal ions of normal cel-
lular processes and their BBB-reduced permeability sig-
nificantly limit their therapeutic success [199]. Yang et al. 
designed an  H2O2-sensitive detection system composed 
of Clioquinol-doped gold NPs-capped mesoporous silica 
[199], and revealed that the conjugation of Clioquinol-
MNPs on the surface of mesoporous silica leads to selec-
tive and sustained Clioquinol release under an increased 
 H2O2 environment (e.g., surrounding of Aβ plaques). 
Furthermore, their nanodevice efficiently crossed the 
BBB, decreased Aβ self-assembly, and reduced microtu-
bular defects, cell membrane disruption, and ROS-medi-
ated apoptosis induced by Aβ40.
Hydrogen  (H2) has been shown to selectively scav-
enge highly cytotoxic ROS. Furthermore, Hydrogen’s 
bio-safety and bio-diffusibility position it ahead of many 
compounds in AD drug discovery. However, the high 
solubility of  H2 and traditional hydrogen administration 
routes, such as the oral intake of hydrogen-rich water, 
inhalation of hydrogen gas, or injection of hydrogen-rich 
saline, do not ensure its accumulation in the brain for 
the time necessary to exert its activity [200]. Zhang et al. 
developed reactive hydrogen-doped palladium NPs and 
evaluated their effects against oxidative stress-induced 
mitochondrial dysfunction in both in  vitro and in  vivo 
models of AD [200]. This was the first time that a nano-
system was shown to be able to perform a self-catalysis 
of carried  H2 and realize an in  situ sustained release of 
bio-reductive hydrogen. This innovative system effec-
tively stores and releases bio-reductive hydrogen to selec-
tively  scavenge.OH in AD cells, inhibit Aβ generation and 
aggregation, reverse synaptic deficits and neuronal death, 
and ameliorate mitochondrial dysfunction and cognitive 
impairment in transgenic AD mice.
Going a step further, Cai et al. recently developed ultr-
asmall superparamagnetic iron oxide NPs (USPIONs) 
coupled to a phenothiazine-based near-infrared (NIR) 
fluorescent dye for both the diagnosis and treatment 
of AD [201]. This compound was shown to effectively 
inhibit the self-aggregation of Aβ and disaggregate pre-
formed Aβ fibrils, as well as exhibit high fluorescence 
enhancement upon binding to aggregate Aβ proteins 
[201]. Thanks to their small size, amyloidogenic proteins, 
such as Aβ peptides, tend to be absorbed on the surface 
of USPIONs, thereby reducing circulating Aβ. Likewise, 
brain cells have been shown to be highly sensitive to 
USPIONs and their responsiveness to an external mag-
netic field is an important advantage to promote brain 
cell uptake. Moreover, the moderate heat emitted from 
USPIONs under the action of a low radiofrequency field 
represents a significant advantage since it increases the 
BBB’s permeability without disturbing its integrity [201]. 
Cai et al. revealed that developed USPIONs can prevent 
Aβ aggregation, disaggregate preformed Aβ fibrils, simul-
taneously perform in vivo NIR fluorescence and MRI of 
Aβ plaques in the brain, and perform a neuroprotective 
effect against Aβ42-induced toxicity.
Importantly, not only is the theragnostic potential of 
MNPs being studied, but also their potential neurotoxic 
effects. Increasing evidence shows the relevance of toxins 
in AD development, such as ultrafine air pollution parti-
cles. Therefore, and since nanomedicine has emerged as 
a promising alternative for AD management, concerns 
have been raised about the potential neurotoxic effects 
of different nanocarriers, especially MNPs. Their small 
size and easy penetration into human tissues by differ-
ent access routes allow their high accumulation in the 
brain. Cerium dioxide NPs have gained much interest in 
recent years because of their radical-scavenging proper-
ties. For these reasons, Wahle et  al. recently evaluated 
the neurotoxic effects of zirconium-doped cerium diox-
ide NPs in two different mice models of AD [202]. The 
continuous inhalation of these nanocarriers promotes 
changes in exploratory motor activity and forced motor 
performance in AD mice and increases GFAP expression 
in healthy mice. Thus, although MNPs represent a prom-
ising therapeutic alternative, these results highlight the 
importance of exhaustive research into their neurotoxic-
ity to ensure therapeutic safety.
Conclusions
Dementias, including AD, are the fifth-leading cause 
of death worldwide, accounting for 2.4 million deaths 
yearly. The expected increase in the number of cases of 
dementia in the next few decades is even more impor-
tant, given that there are currently no effective disease-
modifying treatments for AD [1]. In addition, even 
when clinical trials are initiated, many of them fail to 
discover a new disease-modifying drug to market: 
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of every 100 molecules in clinical AD trials, only one 
reaches the market, compared to the pharmaceuti-
cal industry average ratio of 14.6:1 [1]. Without novel 
promising treatments in sight, increasing numbers of 
cases will pose an undue burden on patients who have 
dementia, their caregivers, and healthcare systems in 
general. The latest drug development pipeline shows 
that, in 2020, there were 121 compounds in clinical tri-
als for the treatment of AD [10]. The lack of success in 
AD drug development reveals the complexity of this 
disease and the current challenges of AD neurophar-
macology research. Suggestions to abandon the amy-
loid hypothesis are increasing and emerging interest is 
focused on combination therapies [10]. Progress in AD 
management depends on innovation, the assessment 
of new candidates, and the implementation of new 
trial approaches. As in other chronic diseases, such as 
cardiovascular disease or cancer, a learning phase pre-
ceded periods of sequential incremental success lead-
ing to meaningful treatments. Therefore, the increase 
of studies of combinations of new biomarkers and drug 
targets, combined with novel research in state-of-the-
art nanocarriers, will pave the future for the more effi-
cient delivery of bioactive molecules. Furthermore, the 
clinical development of biomarkers of AD progression 
to create treatments that are more efficacious will be 
one of the most ambitious challenges for future clinical 
practice. In that regard, recent advances on nanomedi-
cine-drug development and novel diagnostic biomark-
ers could represent a promising alternative in the 
management of AD, as well as other neurodegenerative 
diseases.
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